CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 06, 2026 CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) — CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein […]

Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026 GlobeNewswire January 06, 2026 RADNOR, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD),

Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 06, 2026 CHARLESTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, will

Picard Medical to Begin Rollout of FDA-Cleared Accessory for its SynCardia Total Artificial Heart The new component is designed to enhance comfort for patients as well as further reinforce the safety and reliability of the device GlobeNewswire January 06, 2026 TUCSON, Ariz., Jan. 06, 2026 (GLOBE NEWSWIRE) — Picard Medical, Inc. (NYSE American: PMI) (“Picard”

Sparrow Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Clofutriben for Difficult-to-Control Type 2 Diabetes Clofutriben is a novel, once-daily, oral HSD-1 inhibitor that reduces excess intracellular cortisol, a new precision approach to a common underlying driver of metabolic dysfunction GlobeNewswire January 06, 2026 PORTLAND, Ore., Jan. 06, 2026 (GLOBE NEWSWIRE) —

Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer GlobeNewswire January 06, 2026 Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer IRVINE, CA – January XX, 2026 (GlobeNewswire)

Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 06, 2026 BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1×1 investor meetings at the 44th Annual J.P. Morgan

Apollo to Announce Fourth Quarter and Full Year 2025 Financial Results on February 9, 2026 GlobeNewswire January 06, 2026 NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) plans to release financial results for the fourth quarter and full year 2025 on Monday, February 9, 2026, before the opening of trading on the

(NASDAQ:RXRX), Salt Lake City, Jan. 06, 2026 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13, 10:30am PT at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Management will

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 06, 2026 Salt Lake City, Jan. 06, 2026 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13, 10:30am PT at